As of November 6, 2026, Acurx Pharmaceuticals, Inc. has Schedule 13D or 13G filings on record, none whose latest reports a stake of 5% or more. 2 filings are on record since August 14, 2025 (Schedule 13G/A, November 14, 2025).
Sell to companies like Acurx Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Acurx Pharmaceuticals, Inc. has 2 Schedule 13D or 13G filings on record since 2025-08-14. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Armistice Capital, LLC | 4.99% | 83,233 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Holding shares or following this stake? See who's behind Acurx Pharmaceuticals, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Acurx Pharmaceuticals, Inc. and the records around it.
Acurx Pharmaceuticals, Inc. elsewhere on the record
- Company profile and every filing Apr 2026
- Form D filing Apr 2026
- Form D filing Jun 2025
- Who owns it
Companies that share a holder
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Acurx Pharmaceuticals, Inc.
Get an email when Acurx Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Acurx Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Acurx Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Acurx Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Armistice Capital, LLC | 8.7% | SCHEDULE 13G |
| 2025-11-14 | Armistice Capital, LLC | 4.99% | SCHEDULE 13G/A |
Also on the record for Acurx Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 29, 2026 | Form D, private offering | $4.59M sold | Form D page | Source |
| June 27, 2025 | Form D, private offering | $3.98M sold | Form D page | Source |
| May 20, 2025 | Form D, private offering | — | Form D page | Source |
| March 21, 2025 | Form D, private offering | $3.38M sold | Form D page | Source |
| January 17, 2025 | Form D, private offering | $2.40M sold | Form D page | Source |
Acurx Pharmaceuticals, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Acurx Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.